United Therapeutics (NASDAQ:UTHR) Price Target Raised to $415.00 at UBS Group

Key Points

• UBS Group has raised the price target for United Therapeutics from $385.00 to $415.00, indicating a potential upside of 37.70% from its current price.
• Despite the positive outlook from UBS, other analysts have lowered their price targets, with JPMorgan and Bank of America reducing theirs to $330.00 and $315.00, respectively.
• United Therapeutics reported quarterly earnings of $6.41 per share, missing estimates, with revenue increasing 11.7% year-over-year to $798.60 million.

United Therapeutics (NASDAQ:UTHR - Get Free Report) had its price target increased by investment analysts at UBS Group from $385.00 to $415.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a "buy" rating on the biotechnology company's stock. UBS Group's target price points to a potential upside of 37.70% from the company's current price.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. reduced their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Bank of America reduced their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday, June 11th. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price target on the stock. Morgan Stanley cut their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Finally, Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $382.00.

United Therapeutics Stock Up 0.3%

UTHR opened at $301.39 on Wednesday. The firm has a 50-day moving average price of $295.69 and a 200-day moving average price of $310.03. United Therapeutics has a twelve month low of $266.98 and a twelve month high of $417.82. The company has a market capitalization of $13.60 billion, a price-to-earnings ratio of 11.76, a PEG ratio of 4.55 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the prior year, the firm posted $5.85 earnings per share. The firm's quarterly revenue was up 11.7% on a year-over-year basis. On average, sell-side analysts expect that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, Director Richard Giltner sold 3,036 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the transaction, the director directly owned 19,384 shares in the company, valued at approximately $5,613,606.40. This represents a 13.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $300.00, for a total value of $3,300,000.00. Following the transaction, the executive vice president owned 36,781 shares in the company, valued at $11,034,300. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,681 shares of company stock valued at $24,618,359. 10.30% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Elevation Point Wealth Partners LLC purchased a new position in shares of United Therapeutics during the second quarter worth approximately $53,000. Quadrant Capital Group LLC raised its position in United Therapeutics by 60.8% in the 2nd quarter. Quadrant Capital Group LLC now owns 4,722 shares of the biotechnology company's stock worth $1,357,000 after purchasing an additional 1,786 shares during the period. Vinva Investment Management Ltd raised its position in United Therapeutics by 352.0% in the 2nd quarter. Vinva Investment Management Ltd now owns 39,466 shares of the biotechnology company's stock worth $11,219,000 after purchasing an additional 30,734 shares during the period. Employees Retirement System of Texas bought a new stake in United Therapeutics in the second quarter worth $103,000. Finally, Choreo LLC purchased a new stake in United Therapeutics during the second quarter valued at about $220,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.